BETA
Your AI-Trained Oncology Knowledge Connection!
FDA Grants Accelerated Approval to Asciminib in Ph+ CML in Chronic Phase
Data from the ASC4FIRST trial support the accelerated approval of asciminib in this CML population.
HERC Tool Demonstrates Feasibility in Advancing Equitable Cancer Care
Data presented from a pilot study evaluating HERC validated its usability in measuring equitable practices at leading cancer centers.
FDA Expands Approval for Methotrexate in Pediatric ALL, pJIA Indications
The expanded approval of methotrexate may offer a convenient alternative to pediatric patients who have difficulty swallowing pills.
Gilead Sciences to Withdraw Sacituzumab Govitecan Bladder Cancer Approval Status
Data from TROPiCS-04 did not meet the primary end point of overall survival among those with locally advanced or metastatic urothelial cancer.
STX-478 Yields Efficacy, Tolerability in PI3K-Mutated Advanced Solid Tumors
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 May Show Preferential Binding in PI3K-Mutated Solid Tumors
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
IDE397 Shows Preliminary Efficacy in MTAP+ NSCLC and Urothelial Cancer
Phase 1 expansion data may support potential combination development for IDE397 in NSCLC and urothelial cancer harboring MTAP deletions.
The Evolving Landscape of Prostate Cancer Management
Maha Hussain, MD, FACP, FASCO, spoke about BRCA testing and ctDNA as diagnostic tools and PSMA-imaging and -targeted approaches in prostate cancer.
Empowering Awareness to Address Rising Gynecological Cancer Incidence
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Different Treatment Algorithms for Gastric Cancers May Improve Outcomes
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma
A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.
Maternal Risks Appear Low Despite Increases in Cancer During Pregnancy
Findings from 3 studies combining birth and cancer registers showed postponing childbearing partially correlated with cancer increases in pregnant women.
Evaluating Immunotherapy Options Based on Mutations for NSCLC
Experts discussed the efficacy and durability of immunotherapy responses in patients with NSCLC.
STX-478 May Improve Therapeutic Index Vs Other PI3K Inhibitors in Cancer
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Liquid Biopsy Imaging May Show Benefit in Li-Fraumeni Syndrome Screening
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
DLL3-Targeted ADC Produces Responses in Previously Treated ES-SCLC
Promising phase 1 data appear to support further evaluation of ZL-1310 as a treatment for patients with extensive-stage small cell lung cancer.
Assessing Immunotherapy Options for PD-L1 NSCLC
A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.
PET Imaging Agent Earns FDA Priority Review in Recurrent Glioma
The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.
Zolbetuximab/Chemo Displays PFS, OS Benefits in Gastric Cancer Trials
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
Forming International Collaborative Efforts to Assess Metformin Use in LFS
Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.
Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers
Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.
City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC
Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.
Zolbetuximab Has Benefit in Targeting CLDN18.2 in Gastrointestinal Cancers
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Bria-IMT Regimen Exceeds Survival Data of SOC in Metastatic Breast Cancer
Four of 13 patients with metastatic breast cancer recruited in 2022 for the phase 2 clinical study evaluating Bria-IMT remain in survival follow-up.
Making Intervention Accessible for All Li-Fraumeni Syndrome Populations
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
FDA Accepts NDA Resubmission of Rivoceranib/Camrelizumab in uHCC
The resubmission included an analysis of the phase 3 CARES-310 study, which reported favorable overall survival with the combination therapy in uHCC.
Expert Commentary on the Product Profile of Lazertinib in NSCLC
Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.
Further Research May Explore Systemic Therapy Failure Following RT in NSCLC
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Sound Biologic Foundation May Support Metformin in Li-Fraumeni Syndrome
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Data Show Increasing Systemic Therapy Use in NSCLC Radiotherapy Population
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
